Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.
J Dermatol. 2024 Apr;51(4):552-557. doi: 10.1111/1346-8138.17120. Epub 2024 Jan 31.
Finasteride is commonly used for androgenetic alopecia (AGA) treatment. The aim of this study was to assess the therapeutic maintenance effect of a finasteride every other month (EOM) regimen and analyze clinical and laboratory differences in patients with AGA according to their treatment response. One hundred males with AGA who received finasteride 1 mg daily treatment for a year were enrolled in the study. At 1 year follow-up, treatment responses of patients who completed the visit schedule were assessed using five scales. The patients were assigned to good or bad response groups according to their assessment. Further, they were randomly divided into two groups (daily vs. EOM) and treated with finasteride (1 mg) for 1 more year. At 2 years follow-up, treatment efficacy was assessed. At 1-year follow-up, 36 patients completed the schedule, including eight and three patients in the good and bad response groups, respectively. At the 2-year follow-up, 23 patients completed the schedule, with nine in the daily group and 14 in the EOM group. Changes in global photographic assessment in the second year were 1.33 and 1.29 for the daily and EOM groups, respectively. The daily group showed an elevated hair density and lower concentration of dihydrotestosterone (DHT) and the DHT to testosterone ratio (DHT/T). However, the EOM group showed decreased hair density and elevated DHT and DHT/T. Following treatment response assessment after 1 year of treatment, the good response group showed early onset which was associated with maternal AGA. Analysis of serum androgen hormone magnitude of DHT reduction was much greater (54.4% vs. 44.4%). DHT/T was higher in the bad response group (1.98 vs. 2.33). We concluded that the finasteride EOM regimen showed similar maintenance effects to the daily regimen.
非那雄胺常用于治疗雄激素性脱发(AGA)。本研究旨在评估非那雄胺每两个月(EOM)方案的治疗维持效果,并根据治疗反应分析 AGA 患者的临床和实验室差异。本研究纳入了 100 名接受非那雄胺 1mg 每日治疗 1 年的 AGA 男性患者。在 1 年随访时,使用 5 种量表评估完成访视计划的患者的治疗反应。根据评估结果,将患者分为治疗反应良好和不良组。进一步将患者随机分为每日组和 EOM 组(每组 50 例),并分别接受非那雄胺(1mg)治疗 1 年。在 2 年随访时评估治疗效果。在 1 年随访时,有 36 例患者完成了随访计划,其中治疗反应良好和不良组分别有 8 例和 3 例患者。在 2 年随访时,有 23 例患者完成了随访计划,其中每日组 9 例,EOM 组 14 例。第二年的全球照片评估变化,每日组和 EOM 组分别为 1.33 和 1.29。每日组的毛发密度增加,二氢睾酮(DHT)和 DHT/睾酮比值(DHT/T)降低。然而,EOM 组的毛发密度降低,DHT 和 DHT/T 升高。在治疗 1 年后进行治疗反应评估后,治疗反应良好组的发病时间较早,与母亲的 AGA 有关。DHT 降低的血清雄激素激素幅度分析显示,每日组的降幅更大(54.4%比 44.4%)。DHT/T 在治疗反应不良组中更高(1.98 比 2.33)。我们得出结论,非那雄胺 EOM 方案的维持效果与每日方案相似。